Impending US tariffs signal uncertain future for global pharma, says GlobalData
In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised …
Post
-
-
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The …
-
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the …
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a …
-
AstraZeneca CEO calls for increased European investment in pharma
AstraZeneca CEO Pascal Soriot has urged European governments to increase investment in pharmaceutical innovation, warning of a growing imbalance between …
-
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the …
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a …
-
AstraZeneca CEO calls for increased European investment in pharma
AstraZeneca CEO Pascal Soriot has urged European governments to increase investment in pharmaceutical innovation, warning of a growing imbalance between …
-
Small biotechs shoulder the burdens of an uncertain biopharma sector
Recent US tariffs and federal funding cuts mean a heightened uncertainty for biopharma investors, and small biotechs are set to …
-
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis under the name …
-
Biohaven secures $600m financing as it awaits FDA prodrug decision
Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital …
-
Prilenia and Ferrer to commercialise pridopidine in Europe
Prilenia Therapeutics has signed a partnership and licence agreement with Ferrer to jointly develop and commercialise pridopidine in Europe and …
-
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed …
-
France halts Valneva’s chikungunya vaccine use in seniors
French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after serious …
-
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat adults with moderately …
